



NORWAY

(19) NO
(51) Int Cl.
A61K 31/122 (2006.01)
C07C 50/28 (2006.01)

Norwegian Industrial Property Office


(21)	Translation Published	2016.11.07
(80)	Date of The European Patent Office Publication of the Granted Patent	2016.07.27
(86)	European Application Nr.	11748898.1
(86)	European Filing Date	2011.08.16
(87)	The European Application's Publication Date	2013.06.26
(30)	Priority	2010.08.16, EP, 10008542 2010.12.20, EP, 10015842 2011.04.11, EP, 11003037 2010.08.16, US, 373972 P 2010.12.20, US, 201061424978 P 2011.04.11, US, 201161473835 P
(84)	Designated Contracting States:	AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
(73)	Proprietor	Santhera Pharmaceuticals (Schweiz) AG, Hammerstrasse 49, 4410 Liestal, CH-Sveits
(72)	Inventor	FEURER, Achim, Eselacker 1, 79424 Auggen, DE-Tyskland GUEVEN, Nuri, Wehrstrasse 26, 79618 Rheinfelden, DE-Tyskland HOFFMANN-ENGER, Barbara, Kleinfeldweg 25A, CH-4106 Therwil, CH-Sveits ERB, Michael, Bleichweg 17, CH-4416 Gelterkinden, CH-Sveits DEPPE, Holger, Erlenstrasse 3, CH-4414 Füllinsdorf, CH-Sveits DALLMANN, Robert, Viktoriarain 13, CH-3013 Bern, CH-Sveits HAEFELI, Roman, Wasserstrasse 6, CH-4056 Basel, CH-Sveits HEITZ, Fabrice, 5 rue du moulin, F-68870 Bartenheim, FR-Frankrike
(74)	Agent or Attorney	Håmsø Patentbyrå ANS, Postboks 171, 4302 SANDNES, Norge

(54)	Title	BENZOQUINONE DERIVATIVES FOR THE TREATMENT OF MITCHONDRIAL EYE DISEASES
(56)	References Cited:	EP-A1- 0 788 793 EP-A2- 0 201 196 WO-A2-98/02149 KAYOKO OKAMOTO ET AL: "Synthesis, Metabolism, and in Vitro Biological Activities of 6-(10-Hydroxydecyl)-2, 3-dimethoxy-5-methyl-1, 4-benzoquinone (CV-2619)-Related Compounds", CHEMICAL AND PHARMACEUTICAL BULLETIN, PHARMACEUTICAL SOCIETY OF JAPAN, TOKYO, JP, vol. 36, no. 1, 1 January 1988 (1988-01-01), pages 178-189, XP009143726, ISSN: 0009-2363 DUVEAU D Y ET AL: "Synthesis and characterization of mitoQ and idebenone analogues as mediators of oxygen consumption in mitochondria", BIOORGANIC & MEDICINAL CHEMISTRY, PERGAMON, GB, vol. 18, no. 17, 4 August 2010 (2010-08-04), pages 6429-6441, XP027218831, ISSN: 0968-0896 [retrieved on 2010-08-04] DATABASE CA [Online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; "Stable 6-(10-hydroxydodecyl)-2,3-dimethoxy-5-meth yl-1,4-benzoquinone microcrystals", XP002668984, retrieved from STN Database accession no. 1983:476854 & DATABASE WPI Week 198325 Thomson Scientific, London, GB; AN 1983-59523K & JP 58 077839 A (TAKEDA CHEM IND LTD) 11 May 1983 (1983-05-11) Daniel Jarovsky ET AL: "Mitochondrial Diseases: A review", Reviewing Basic Sciences, 1 January 2006 (2006-01-01), pages 343-350, XP055018708, Retrieved from the Internet: URL:http://apps.einstein.br/REVISTA/arquiv os/PDF/Einstein_vol4_n4_2006_p343.pdf [retrieved on 2012-02-08]

Enclosed is a translation of the patent claims in Norwegian. Please note that as per the Norwegian Patents Acts, section 66i the patent will receive protection in Norway only as far as there is agreement between the translation and the language of the application/patent granted at the EPO. In matters concerning the validity of the patent, language of the application/patent granted at the EPO will be used as the basis for the decision. The patent documents published by the EPO are available through Espacenet (<http://worldwide.espacenet.com>) or via the search engine on our website here: <https://search.patentstyret.no/>

P a t e n t k r a v


1. Forbindelse representert ved den generelle formelen (I)



(I)

og enantiomerne, tautomerne, oppløsningene eller de farmasøytisk akseptable saltene derav, hvor

R¹ er en substituent representert ved formelen (II):



(II)

hvor

både R⁵ og R⁶ er hydrogenatomer, eller

R⁵ er et hydrogenatom og R⁶ er en etylgruppe, eller

både R⁵ og R⁶ er metylgrupper,

R² er en metylgruppe,

R³ er en metoksygruppe, og

R⁴ er en metoksygruppe;


for bruk i behandlingen av en mitokondriesykdom, hvor mitokondriesykdommen er valgt fra gruppen bestående av Lebers sykdom (LHON), autosomal dominant optisk atrofi (DOA), makuladegenerasjon, glaukom, retinopati, katarakt og papilledruser (ODD).

2. Forbindelse for bruk ifølge krav 1, hvor både R⁵ og R⁶ er hydrogenatomer.

3. Forbindelse for bruk ifølge krav 2, hvor forbindelsen administreres oralt.

4. Forbindelse for bruk ifølge krav 3, hvor mitokondriesykdommen er valgt fra gruppen bestående av Lebers sykdom (LHON), autosomal dominant optisk atrofi (DOA), makuladegenerasjon og glaukom.

5. Bruk av en forbindelse ifølge generell formel (I)



hvor R¹ til R⁴ er definert som i krav 1 for fremstilling av et medikament i behandlingen av en mitokondriesykdom, hvor mitokondriesykdommen er valgt fra en gruppe bestående av Lebers sykdom (LHON), autosomal dominant optisk atrofi (DOA), makuladegenerasjon, glaukom, retinopati, katarakt og papilledruser (ODD).